Bayer AG, of Leverkusen, Germany, said data from its study of children (infants) younger than 2 years of age were presented at the 2014 Radiological Society of North America Scientific Assembly and Annual Meeting. The primary endpoint of the study was the evaluation of the pharmacokinetics (PK) of Gadavist (gadobutrol) injection in plasma at the standard dose of 0.1 mmol/kg body weight.